{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:47:08Z","timestamp":1762102028953},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ymgme.2017.04.004","type":"journal-article","created":{"date-parts":[[2017,4,9]],"date-time":"2017-04-09T02:30:16Z","timestamp":1491705016000},"page":"138-149","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis"],"prefix":"10.1016","volume":"121","author":[{"given":"Jordi","family":"P\u00e9rez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Morales-Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"L\u00f3pez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Hermida-Ameijeiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Molt\u00f3-Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1993","series-title":"Mucopolysaccharidosis Type I. 2010\/03\/20 ed","author":"Clarke","key":"10.1016\/j.ymgme.2017.04.004_bb0005"},{"issue":"6","key":"10.1016\/j.ymgme.2017.04.004_bb0010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","article-title":"Cumulative incidence rates of the mucopolysaccharidoses in Germany","volume":"28","author":"Baehner","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/adc.2007.135772","article-title":"Incidence and prevalence of mucopolysaccharidosis type 1 in the Irish republic","volume":"94","author":"Murphy","year":"2009","journal-title":"Arch. Dis. Child."},{"issue":"11","key":"10.1016\/j.ymgme.2017.04.004_bb0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1651-2227.2008.00965.x","article-title":"Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence","volume":"97","author":"Malm","year":"2008","journal-title":"Acta Paediatr."},{"issue":"8","key":"10.1016\/j.ymgme.2017.04.004_bb0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/gtmb.2011.0307","article-title":"The live-birth prevalence of mucopolysaccharidoses in Estonia","volume":"16","author":"Krabbi","year":"2012","journal-title":"Genet. Test. Mol. Biomarkers"},{"issue":"2","key":"10.1016\/j.ymgme.2017.04.004_bb0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s13353-014-0262-5","article-title":"Prevalence rates of mucopolysaccharidoses in Poland","volume":"56","author":"Jurecka","year":"2015","journal-title":"J. Appl. Genet."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2017.04.004_bb0035","first-page":"102","article-title":"Mucopolysaccharidosis type I","volume":"12","author":"Wraith","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"10","key":"10.1016\/j.ymgme.2017.04.004_bb0040","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/gim.2014.25","article-title":"The natural history of MPS I: global perspectives from the MPS I registry","volume":"16","author":"Beck","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.04.004_bb0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2017.04.004_bb0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ymgme.2017.04.004_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10545-006-0490-x","article-title":"Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy","volume":"30","author":"Cox-Brinkman","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0070","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1542\/peds.2009-1728","article-title":"Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up","volume":"125","author":"Gabrielli","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.ymgme.2017.04.004_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","article-title":"Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings","volume":"109","author":"Laraway","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","article-title":"Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships","volume":"10","author":"Al-Sannaa","year":"2015","journal-title":"Orphanet J Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2017.04.004_bb0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ymgme.2016.02.003","article-title":"Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI","volume":"117","author":"Lin","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"39","key":"10.1016\/j.ymgme.2017.04.004_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.ymgme.2017.04.004_bb0095","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.ymgme.2017.04.004_bb0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ymgme.2017.04.004_bb0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10545-012-9538-2","article-title":"Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans","volume":"36","author":"de Ru","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2017.04.004_bb0110","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10545-007-0551-9","article-title":"Enzyme replacement therapy in 12 patients with MPS I-H\/S with homozygous p.Leu490Pro mutation","volume":"30","author":"Arora","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2017.04.004_bb0115","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2017.04.004_bb0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5604\/15093492.1084240","article-title":"Evaluation of motor response in mucopolysaccharidosis patients treated with enzyme replacement therapy","volume":"15","author":"Matos","year":"2013","journal-title":"Ortop. Traumatol. Rehabil."},{"key":"10.1016\/j.ymgme.2017.04.004_bb0125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13023-015-0255-4","article-title":"Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome","volume":"10","author":"Pal","year":"2015","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.ymgme.2017.04.004_bb0130","article-title":"The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis","author":"Dualibi","year":"2015","journal-title":"Braz. J. Otorhinolaryngol."},{"issue":"10","key":"10.1016\/j.ymgme.2017.04.004_bb0135","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archopht.125.10.1353","article-title":"Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience","volume":"125","author":"Pitz","year":"2007","journal-title":"Arch. Ophthalmol."},{"issue":"5","key":"10.1016\/j.ymgme.2017.04.004_bb0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00247-008-0788-y","article-title":"Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI","volume":"38","author":"Schumacher","year":"2008","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.ymgme.2017.04.004_bb0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-8-71","article-title":"Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses","volume":"8","author":"Lin","year":"2013","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-016-0437-8","article-title":"Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series","volume":"11","author":"Horovitz","year":"2016","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000337492","article-title":"Visual dysfunction of type I and VI mucopolysaccharidosis patients evaluated with visual evoked cortical potential","volume":"3","author":"Gomes","year":"2012","journal-title":"Case Rep. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ymgme.2017.04.004_bb0160","first-page":"S19","article-title":"International patient survey demonstrates treatment satisfaction for muco-polysaccharidosis I","volume":"96","author":"Cox","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.04.004_bb0165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.dib.2015.08.004","article-title":"Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I","volume":"5","author":"Dickson","year":"2015","journal-title":"Data Brief"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2017.04.004_bb0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymgme.2015.07.005","article-title":"Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I","volume":"116","author":"Dickson","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.12891\/ceog1845.2015","article-title":"Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement therapy","volume":"42","author":"Castorina","year":"2015","journal-title":"Clin. Exp. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0185","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10545-006-0237-8","article-title":"Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I","volume":"29","author":"Anbu","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2017.04.004_bb0190","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s10545-005-0211-x","article-title":"Mucopolysaccharidosis I under enzyme replacement therapy with laronidase\u2013a mortality case with autopsy report","volume":"28","author":"Lin","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2017.04.004_bb0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2011.03.016","article-title":"Laronidase replacement therapy improves myocardial function in mucopolysaccharidosis I","volume":"103","author":"Harada","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"13","key":"10.1016\/j.ymgme.2017.04.004_bb0200","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ajmg.a.32317","article-title":"Decreased corneal opacity and improved vision in a patient with mucopolysaccharidosis I (Hurler-Scheie) treated with enzyme replacement therapy (laronidase, Aldurazyme)","volume":"146A","author":"Caceres-Marzal","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0205","first-page":"55","article-title":"Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis","volume":"36","author":"Velez-Diaz-Pallares","year":"2012","journal-title":"Farm. Hosp."},{"issue":"4","key":"10.1016\/j.ymgme.2017.04.004_bb0210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.09.006","article-title":"Scheie syndrome diagnosed after cerebral infarction","volume":"21","author":"Fujii","year":"2012","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2017.04.004_bb0215","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1007\/s10545-009-1265-y","article-title":"Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression","volume":"32","author":"Illsinger","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"19","key":"10.1016\/j.ymgme.2017.04.004_bb0220","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/ajmg.a.32294","article-title":"Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression","volume":"146A","author":"Munoz-Rojas","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2017.04.004_bb0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/8904_2014_316","article-title":"Laronidase replacement therapy and left ventricular function in mucopolysaccharidosis I","volume":"16","author":"Harada","year":"2014","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2017.04.004_bb0230","first-page":"371","article-title":"Sudden vision loss in a mucopolysaccharidosis I patient receiving enzyme replacement therapy","volume":"22","author":"Yosunkaya","year":"2011","journal-title":"Genet. Couns."},{"issue":"10","key":"10.1016\/j.ymgme.2017.04.004_bb0235","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jfma.2014.05.009","article-title":"Mucopolysaccharidosis I (Scheie syndrome): a rare cause of severe aortic stenosis in a 31-year-old man","volume":"114","author":"Lin","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"issue":"4","key":"10.1016\/j.ymgme.2017.04.004_bb0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","article-title":"Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: a comprehensive meta-analysis of pooled data from multiple studies","volume":"117","author":"Xue","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.04.004_bb0245","doi-asserted-by":"crossref","first-page":"14068","DOI":"10.1038\/mtm.2014.68","article-title":"A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I","volume":"2","author":"Mendez","year":"2015","journal-title":"Mol. Ther. Methods Clin Dev."},{"issue":"4","key":"10.1016\/j.ymgme.2017.04.004_bb0250","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005792-198807000-00002","article-title":"Respiratory complications of mucopolysaccharide storage disorders","volume":"67","author":"Semenza","year":"1988","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.ymgme.2017.04.004_bb0255","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ymgme.2017.04.004_bb0260","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ymgme.2015.12.220","article-title":"Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis I","volume":"117","author":"Chen","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2017.04.004_bb0265","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.ymgme.2017.04.004_bb0270","article-title":"Developing methodology for the creation of clinical practice guidelines for rare diseases: a report from RARE-Bestpractices","volume":"3","author":"Pai","year":"2015","journal-title":"Rare Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217300574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217300574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T09:42:55Z","timestamp":1658914975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217300574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1096719217300574"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.04.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}